

Monitoring of precancerous cervical lesions at colposcopy using a new non-invasive technique

Submission date 13/04/2021	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 27/01/2022	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 15/01/2025	Condition category Urological and Genital Diseases	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

This study is being done to improve the management of women diagnosed with cervical intraepithelial neoplasia grade 2 (CIN2). Cervical intraepithelial neoplasia is a precancerous condition where abnormal cells grow on the surface of the cervix. CIN 2 means two-thirds of the thickness of the cervical surface layer is affected by abnormal cells. In the past this condition was treated by removal of the disease. However, as we have learnt more about this condition we now know that the majority of these cases resolve spontaneously. This has meant that these women can be offered a watchful waiting approach/expectant management approach. Indeed there has been much work that has now led to clinicians advocating for conservative management. A new non-invasive approach enables doctors to monitor these lesions at a molecular level without the need for a biopsy (tissue sample). This means that such women can be effectively managed in the community without the requirement for an intrusive exam/test.

Who can participate?

Female patients with more than moderate dyskaryosis (change of appearance of the cells that cover the surface of the cervix), between 25 and 35 years of age, with confirmed CIN2 in a single quadrant of the cervix

What does the study involve?

One baseline and up to four further colposcopic examinations during the course of the year. Colposcopy is a procedure to visually examine the cervix using a colposcope. This is one or two additional follow-up examinations in comparison to the normal 6 monthly follow-up appointments for patients who are currently having conservative management for CIN2.

What are the possible benefits and risks of participating?

There are no immediate clinical benefits in this study but the information collected could be used to help decide which women may need treatment in the future. The main disadvantage is a slightly longer procedure (less than 5 minutes) and the two extra visits to the colposcopy clinic for a colposcopic exam. The nitrocellulose absorbent paper is made of material that is perfectly safe to use in humans. There are no other risks in taking part.

Where is the study run from?

Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital (UK)

When is the study starting and how long is it expected to run for?

May 2020 to December 2022

Who is funding the study?

The British Society For Colposcopy and Cervical Pathology (BSCCP) (UK)

Who is the main contact?

1. Dr Robin Crawford, robin.crawford@nhs.net
2. Dr Martin Thomas, martin.thomas15@nhs.net
3. Dr Tulay Gulsen, tulay.gulsen@nhs.net

Contact information

Type(s)

Scientific

Contact name

Dr Robin Crawford

Contact details

Chief Investigator
Cambridge University Hospitals NHS Foundation Trust
Box 242 Addenbrookes Hospital
Cambridge
United Kingdom
CB2 0QQ
+44 (0)1223216251
robin.crawford@nhs.net

Type(s)

Principal Investigator

Contact name

Dr Aslam Shiraz

Contact details

Principal Investigator
Cambridge University Hospitals NHS Foundation Trust
Box 242 Addenbrookes Hospital
Cambridge
United Kingdom
CB2 0QQ
+44 (0)1223216251
mas202@cam.ac.uk

Type(s)

Scientific

Contact name

Dr Martin Thomas

Contact details

Senior Clinical Trial Coordinator:
Cambridge University Hospitals NHS Foundation Trust
Box 242 Addenbrookes Hospital
Cambridge
United Kingdom
CB2 0QQ
+44 (0)1223 349707
martin.thomas15@nhs.net

Type(s)

Scientific

Contact name

Dr Tulay Gulsen

Contact details

Clinical Trial Coordinator
Cambridge University Hospitals NHS Foundation Trust
Box 242 Addenbrookes Hospital
Cambridge
United Kingdom
CB2 0QQ
+44 (0)1223 256364
tulay.gulsen@nhs.net

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

272534

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

CPMS 44602, IRAS 272534

Study information

Scientific Title

Monitoring of cervical lesions at colposcopy using a novel non-invasive technique for monitoring of CIN2 lesions (a pilot/feasibility study)

Study objectives

The purpose of this study is to examine how best to treat a condition called cervical intraepithelial neoplasia, which is also referred to as CIN2, and is a condition that exists before fully developed cancer cells are formed. The plan is to assess the feasibility of treating CIN2 with watchful waiting rather than surgical treatment. Currently, patients diagnosed with CIN2 are offered the choice of watching and waiting to see what happens as there is more than a 50% chance that the condition will resolve itself without any intervention being necessary. However, up till now, there is no effective way to monitor this condition that isn't invasive. To improve the way we keep an eye on how this condition is developing, or not, we have a new approach. We plan to offer patients the opportunity to have the top few cells lifted onto a small piece of nitrocellulose paper. This procedure is called cervical cell lift. In the laboratory, technicians are able to analyse the cell lifts so that the cells can be examined in a way that is as near as how they would look inside the body. This approach of keeping the cells together in their natural relationship to other cells on the cervix may be more useful than looking at individual cells. Researchers think this method of examining a cervical cell sample (called a 'template') may improve the way they are able to diagnose a patient's condition and monitor whether it is getting better or worse in a more meaningful way.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 04/05/2020, East of England Cambridge & Hertfordshire Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK; +44 (0)20 797 22545; cambsandherts.rec@hra.nhs.uk), REC ref: 20/EE/0082

Study design

Non-randomized; Both; Design type: Screening, Cellular, Management of Care, Active Monitoring, Clinical Laboratory Study

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Hospital

Study type(s)

Diagnostic

Participant information sheet

Not available in web format, please use the contact details to request a participant information sheet.

Health condition(s) or problem(s) studied

Cervical intraepithelial neoplasia [CIN], grade II

Interventions

If enrolled on the study after CIN2 diagnosis:

1. Primary visit for colposcopy – CIN2 identified, acetowhite photograph and Patch taken

followed by biopsy

2. 3-month visit for colposcopy – Patch, acetowhite photograph taken and colposcopy done to ensure no change in lesion and comparison with previous photograph of acetowhite change
3. 6-month visit for colposcopy - Patch, acetowhite photograph taken and colposcopy done to ensure no change in lesion and comparison with previous photograph of acetowhite change
4. 9-month visit for colposcopy - Patch, acetowhite photograph taken and colposcopy done to ensure no change in lesion and comparison with previous photograph of acetowhite change
5. 1-year visit for colposcopy – Patch, acetowhite photograph taken and either further biopsy or excisional treatment as per colposcopist impression

If enrolled on the study from the pre-existing clinical pathway, participants will start the study at either the 3-month visit (-/+ 2 weeks) or the 6-month routine clinical visit (-/+ 2 weeks) following CIN2 diagnosis.

Intervention Type

Other

Primary outcome measure

1. CIN2 lesions identified using colposcopy/cytology/histology and cell lift at 0 months (colposcopy cell lift and biopsy), 3 months (colposcopy and cell lift), 6 months (colposcopy, cytology and cell lift), 9 months (colposcopy and cell lift), and 12 months colposcopy cell lift and biopsy)
2. Biomarker patterns consistent with lesion regression/progression identified using immunohistochemistry at 0, 3, 6, 9 and 12 months

Secondary outcome measures

There are no secondary outcome measures

Overall study start date

04/05/2020

Completion date

31/12/2022

Eligibility

Key inclusion criteria

All patients who are <35 years of age AND are CIN2 positive on biopsy AND have only single quadrant disease

Participant type(s)

Patient

Age group

Adult

Upper age limit

35 Years

Sex

Female

Target number of participants

Planned Sample Size: 10; UK Sample Size: 10

Total final enrolment

14

Key exclusion criteria

1. Patients >35 years
2. Patients who are pregnant
3. Patients who are immunosuppressed/are HIV positive
4. Patients who cannot give informed consent
5. Patients who are allergic to nail varnish/have been told they are allergic to nitrocellulose

Date of first enrolment

07/04/2021

Date of final enrolment

24/08/2022

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Addenbrooke's Hospital

Hills Road

Cambridge

United Kingdom

CB2 0QQ

Sponsor information

Organisation

Cambridge University Hospitals NHS Foundation Trust

Sponsor details

Addenbrookes Hospital

Hills Road

Cambridge

England

United Kingdom
CB2 0QQ
+44 (0) 1223 348 005
research@addenbrookes.nhs.uk

Sponsor type

Hospital/treatment centre

Website

<http://www.cuh.org.uk/>

ROR

<https://ror.org/04v54gj93>

Funder(s)

Funder type

Other

Funder Name

British Society for Colposcopy and Cervical Pathology

Alternative Name(s)

BSCCP

Funding Body Type

Private sector organisation

Funding Body Subtype

Associations and societies (private and public)

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal in 2022/2023.

Intention to publish date

31/12/2024

Individual participant data (IPD) sharing plan

The data-sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol file	version 4	21/01/2022	11/04/2022	No	No
HRA research summary			26/07/2023	No	No